{"log_id": 6646274262439657239, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 2.1e-05, "average": 0.997339, "min": 0.983123}, "location": {"width": 688, "top": 406, "height": 68, "left": 496}, "words": "恩曲他滨替诺福韦片说明书"}, {"probability": {"variance": 0.004377, "average": 0.981626, "min": 0.717082}, "location": {"width": 528, "top": 509, "height": 38, "left": 573}, "words": "请仃细阅读说明书并在医师指导下使用"}, {"probability": {"variance": 5e-06, "average": 0.992804, "min": 0.990627}, "location": {"width": 61, "top": 583, "height": 34, "left": 804}, "words": "警告"}, {"probability": {"variance": 0.044579, "average": 0.839597, "min": 0.399454}, "location": {"width": 450, "top": 651, "height": 34, "left": 256}, "words": "乳酸中毒严重肝户大伴脂肪变性"}, {"probability": {"variance": 0.022405, "average": 0.920845, "min": 0.486407}, "location": {"width": 1106, "top": 717, "height": 34, "left": 308}, "words": "单独使月核苷类似物(包括恩由他滨背诺福书的成份之一宫马酸替诺唱韦二吡呋酯》治疗或联"}, {"probability": {"variance": 0.013609, "average": 0.947558, "min": 0.426549}, "location": {"width": 1156, "top": 752, "height": 34, "left": 256}, "words": "用其他抗逆转录病毒药物治疗时,曾有发生乳酸性酸中毒和严肝肿大伴脂肪变性的报告,包括出"}, {"probability": {"variance": 0.011419, "average": 0.955464, "min": 0.469664}, "location": {"width": 1152, "top": 791, "height": 29, "left": 256}, "words": "现致死病例,这些病例大多数发生在女性中。肥胖及对核苷的长期暴露可能是危险因素,在有已知"}, {"probability": {"variance": 0.009286, "average": 0.958076, "min": 0.470876}, "location": {"width": 1159, "top": 825, "height": 32, "left": 251}, "words": "肝病危险因素的患者中给予核苷类似物时要特别注意:然面,在没有已知危险因素的患者中也曾经"}, {"probability": {"variance": 0.010346, "average": 0.96475, "min": 0.5154}, "location": {"width": 1156, "top": 859, "height": 34, "left": 253}, "words": "有病例报告。任何患者的临床或实验室结果如果提示有乳酸性酸中毒或显著的肝毒性(可能包括肝"}, {"probability": {"variance": 0.006903, "average": 0.95797, "min": 0.632019}, "location": {"width": 919, "top": 893, "height": 34, "left": 251}, "words": "肿大和脂肪变性,即便转氨酶没有显著升高),应暂停思曲他滨替诺福韦治疗"}, {"probability": {"variance": 0.001015, "average": 0.980183, "min": 0.884124}, "location": {"width": 400, "top": 960, "height": 34, "left": 253}, "words": "HIV-1和乙肝病毒合并感染的患者"}, {"probability": {"variance": 0.012318, "average": 0.939664, "min": 0.564415}, "location": {"width": 1097, "top": 1024, "height": 34, "left": 304}, "words": "建议所有HV-1感染者在开始抗逆转录病毒治疗前检测乙肝病毒(HBV、恩曲他滨替诺福韦"}, {"probability": {"variance": 0.024597, "average": 0.903813, "min": 0.356601}, "location": {"width": 1156, "top": 1060, "height": 34, "left": 253}, "words": "末被批准月于治疗慢性HBV感染,在HBV和HIV-1合并感染患者中曲他滨诺福韦的安全性和行"}, {"probability": {"variance": 0.009916, "average": 0.941236, "min": 0.567578}, "location": {"width": 1154, "top": 1097, "height": 32, "left": 251}, "words": "效尚未得到证实:HBV和HV-1合感染的息者在中断恩曲滨替诺福书治疗之后,曾出现严重的"}, {"probability": {"variance": 0.014673, "average": 0.935459, "min": 0.462712}, "location": {"width": 1161, "top": 1131, "height": 34, "left": 251}, "words": "乙型肝炎急性恶化的报告。部分线受恩曲滨治疗的感染HBV的患者乙型肝炎恶化伴随肝代偿先调"}, {"probability": {"variance": 0.014519, "average": 0.943785, "min": 0.479253}, "location": {"width": 1134, "top": 1166, "height": 34, "left": 260}, "words": "扣肝衰竭,对合并感染HIV-1和HEV后来中断惠曲他滨替诺福韦治疗的患者必须严密监测肝功能"}, {"probability": {"variance": 0.017204, "average": 0.931308, "min": 0.496272}, "location": {"width": 1154, "top": 1202, "height": 32, "left": 251}, "words": "包括临床及实验室随访,在停止治疗后还要持续至少几个月的时间。如果条件适当,思者可能需要"}, {"probability": {"variance": 0.001856, "average": 0.98067, "min": 0.847413}, "location": {"width": 297, "top": 1239, "height": 29, "left": 249}, "words": "重新开始抗乙肝病毒治疗"}, {"probability": {"variance": 0.000101, "average": 0.995426, "min": 0.959648}, "location": {"width": 381, "top": 1303, "height": 29, "left": 246}, "words": "新出现的或更严重的肾功能损害"}, {"probability": {"variance": 0.02517, "average": 0.902394, "min": 0.416659}, "location": {"width": 1106, "top": 1367, "height": 36, "left": 299}, "words": "恩曲他滨和福韦主要通过肾脏消除。用富马酸替诺福韦二吡呋酯时,曾有其引起肾功能"}, {"probability": {"variance": 0.028748, "average": 0.9128, "min": 0.379422}, "location": {"width": 1161, "top": 1403, "height": 34, "left": 242}, "words": "损害的极告,括出现急性肾衰和 Fanconi综合征(肾小管损伤伴严重的低血症)的病例参见"}, {"probability": {"variance": 0.001915, "average": 0.977745, "min": 0.838718}, "location": {"width": 315, "top": 1440, "height": 29, "left": 256}, "words": "【不良反应】:上市后经验"}, {"probability": {"variance": 0.008082, "average": 0.960969, "min": 0.493112}, "location": {"width": 1079, "top": 1504, "height": 34, "left": 297}, "words": "建议在开始治疗前以放使用恩曲他滨替诺福韦治疗期同临床上适当时计算出所有患者的肌酐"}, {"probability": {"variance": 0.006502, "average": 0.960089, "min": 0.680679}, "location": {"width": 1145, "top": 1538, "height": 34, "left": 240}, "words": "清除率行功能损害风险的患者,包括先前在接受阿德福韦酯治疗时经历过肾事件的患者"}, {"probability": {"variance": 0.052445, "average": 0.800008, "min": 0.395832}, "location": {"width": 464, "top": 1575, "height": 36, "left": 240}, "words": "应定期算肌酐清除率和血清磷"}, {"probability": {"variance": 0.023355, "average": 0.91608, "min": 0.476211}, "location": {"width": 1106, "top": 1639, "height": 34, "left": 294}, "words": "建议对所有机管清除率在30至49mL/分钟的患者调整恩曲他滨替诺福韦的给药间期,并切"}, {"probability": {"variance": 0.032469, "average": 0.899855, "min": 0.437272}, "location": {"width": 1161, "top": 1673, "height": 34, "left": 240}, "words": "测肾功能(见【用法用量】)在按照剂量指导接受恩生他滨著诺福韦治疗的肾功能损害患者"}, {"probability": {"variance": 0.030558, "average": 0.909217, "min": 0.370049}, "location": {"width": 1156, "top": 1705, "height": 38, "left": 242}, "words": "中、前还没有用的安全性或疗效数据,所以应当对恩出滨替诺韦治疗的潜在效用和肾毒性"}, {"probability": {"variance": 0.027215, "average": 0.886262, "min": 0.369828}, "location": {"width": 1159, "top": 1739, "height": 38, "left": 240}, "words": "的潜在风险进行是估,肌酐清除率小于30m/分钟或需血液透析的患者小应服用恩曲他滨话福"}, {"probability": {"variance": 0.012227, "average": 0.955284, "min": 0.532405}, "location": {"width": 948, "top": 1808, "height": 36, "left": 290}, "words": "果目前或近期使用过有肾性的制剂,应当避免使用恩曲他滨替诺福韦治疗"}, {"probability": {"variance": 2.9e-05, "average": 0.996229, "min": 0.983643}, "location": {"width": 189, "top": 1874, "height": 32, "left": 242}, "words": "与其他药物联用"}], "language": 3}